Doctors provide lifeline to dialysis patients (The Westerly Sun)

WESTERLY - Some people may not even be aware that there is a place locally where those suffering kidney failure can get the care they require to keep them alive.

Transplant drug preserves kidneys, avoids toxicity (EurekAlert!)

( Emory University ) The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

Forest Laboratories Receives Decision From FDA For Supplemental New Drug Application For Bystolic(R) (Medical News Today)

Forest Laboratories, Inc. (NYSE: FRX) announced that the U.S. Food and Drug Administration (FDA) did not approve the additional indication for Bystolic(R) (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company's Supplemental New Drug Application (sNDA). Bystolic is currently approved in the US for the treatment of hypertension...

Blog: Local Nurse Travels To Haiti (WLWT-TV Cincinnati)

Sharon French is a quality coordinator for Regency Hospital in Cincinnati. She used to practice in pre-hospital/trauma care and worked as an EMT with the City of Edgewood. She was also a part of the medical assistance team with the Red Cross for several years.

Novartis Drug Tasigna(R) Receives FDA Priority Review For Newly Diagnosed Patients With Early-Stage Chronic Myeloid ... (Medical News Today)

Novartis announced that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment ...

Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid ... (redOrbit)

EAST HANOVER, N.J., Feb.

Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid ... (PR Newswire via Yahoo! Finance)

Novartis announced today that Tasigna® 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.